CL2017003427A1 - Anticuerpos para cd40 - Google Patents

Anticuerpos para cd40

Info

Publication number
CL2017003427A1
CL2017003427A1 CL2017003427A CL2017003427A CL2017003427A1 CL 2017003427 A1 CL2017003427 A1 CL 2017003427A1 CL 2017003427 A CL2017003427 A CL 2017003427A CL 2017003427 A CL2017003427 A CL 2017003427A CL 2017003427 A1 CL2017003427 A1 CL 2017003427A1
Authority
CL
Chile
Prior art keywords
antibodies
rllb
tnvention
administrating
union
Prior art date
Application number
CL2017003427A
Other languages
English (en)
Inventor
Aaron P Yamniuk
Bryan C Barnhart
Brigitte Devaux
Brenda L Stevens
Shannon L Okada
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56322325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2017003427A1 publication Critical patent/CL2017003427A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE ANTICUERPOS AGONISTAS, O PORCIONES DE UNIÓN AL ANTÍGENO DEL MISMO QUE SE UNEN A CD40 HUMANO. TALES ANTICUERPOS COMPRENDEN OPCIONALMENTE REGIONES FC CON ESPECIFICIDAD MEJORADA PARA FC?RLLB. LA INVENCIÓN TAMBIÉN PROPORCIONA MÉTODOS PARA EL TRATAMIENTO DE CÁNCER O INFECCIÓN CRÓNICA ADMINISTRANDO LOS ANTICUERPOS DE LA TNVENCIÓN A UN SUJETO EN NECESIDAD DEL MISMO.</p>
CL2017003427A 2015-06-29 2017-12-28 Anticuerpos para cd40 CL2017003427A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186076P 2015-06-29 2015-06-29
US201562252615P 2015-11-09 2015-11-09

Publications (1)

Publication Number Publication Date
CL2017003427A1 true CL2017003427A1 (es) 2018-05-04

Family

ID=56322325

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017003427A CL2017003427A1 (es) 2015-06-29 2017-12-28 Anticuerpos para cd40
CL2022001189A CL2022001189A1 (es) 2015-06-29 2022-05-04 Anticuerpos para cd40. (divisional de solicitud n° 2017003427)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022001189A CL2022001189A1 (es) 2015-06-29 2022-05-04 Anticuerpos para cd40. (divisional de solicitud n° 2017003427)

Country Status (18)

Country Link
US (4) US20180142030A1 (es)
EP (1) EP3313880B1 (es)
JP (2) JP7350467B2 (es)
KR (1) KR102671348B1 (es)
CN (2) CN115838427A (es)
AU (2) AU2016285913B2 (es)
BR (1) BR112017027549A2 (es)
CA (1) CA2990012A1 (es)
CL (2) CL2017003427A1 (es)
CO (1) CO2018000809A2 (es)
EA (1) EA035268B1 (es)
ES (1) ES3039629T3 (es)
HK (1) HK1252666A1 (es)
IL (1) IL256499B (es)
MX (2) MX395257B (es)
PE (1) PE20180315A1 (es)
WO (1) WO2017004006A1 (es)
ZA (1) ZA201708704B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
CA2957146A1 (en) 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
CN107922500A (zh) * 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
ES2985566T3 (es) 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
AU2018278051A1 (en) 2017-06-01 2020-01-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
JP7059388B2 (ja) * 2018-03-23 2022-04-25 イーライ リリー アンド カンパニー 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体
EP3823987A4 (en) * 2018-07-20 2022-03-02 Eucure (Beijing) Biopharma Co., Ltd ANTI-CD40 ANTIBODIES AND USES THEREOF
CN112739371A (zh) * 2018-07-26 2021-04-30 百时美施贵宝公司 用于治疗癌症的lag-3组合疗法
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
BR112021009835A2 (pt) * 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
US20240254248A1 (en) 2018-11-30 2024-08-01 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
US12365740B2 (en) 2019-04-10 2025-07-22 Nankai University Anti-CD40 antibodies and uses thereof
CN115485302A (zh) * 2020-03-09 2022-12-16 百时美施贵宝公司 具有增强的激动剂活性的针对cd40的抗体
CN115956086A (zh) * 2020-05-06 2023-04-11 萨摩亚商柏沛生医股份有限公司 用于针对癌症及传染病的免疫疗法的融合蛋白
CN115403670B (zh) * 2021-05-26 2026-03-10 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
EP4384276A4 (en) * 2021-08-10 2025-06-25 Apexigen, Inc. Biomarkers for cd40 agonist therapy
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2012087928A2 (en) * 2010-12-20 2012-06-28 The Rockefeller University Modulating agonistic tnfr antibodies
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
CN105611944A (zh) 2013-12-20 2016-05-25 豪夫迈·罗氏有限公司 抗ang2抗体和cd40激动剂的组合疗法
AU2015237864B2 (en) 2014-03-24 2020-12-03 Cancer Research Technology Limited Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
CN107922500A (zh) * 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
ES2985566T3 (es) * 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada

Also Published As

Publication number Publication date
JP2018526978A (ja) 2018-09-20
US20180142030A1 (en) 2018-05-24
ES3039629T3 (en) 2025-10-23
JP7350467B2 (ja) 2023-09-26
EP3313880A1 (en) 2018-05-02
EA035268B1 (ru) 2020-05-22
US20210054091A1 (en) 2021-02-25
AU2022228155A1 (en) 2022-11-10
US20190248911A1 (en) 2019-08-15
ZA201708704B (en) 2019-08-28
HK1252666A1 (zh) 2019-05-31
IL256499B (en) 2021-12-01
CL2022001189A1 (es) 2023-01-20
CO2018000809A2 (es) 2018-04-19
JP2022028666A (ja) 2022-02-16
AU2016285913A1 (en) 2018-02-15
KR20180021834A (ko) 2018-03-05
US10844130B2 (en) 2020-11-24
KR102671348B1 (ko) 2024-05-30
CN107771184A (zh) 2018-03-06
EA201890175A1 (ru) 2018-06-29
PE20180315A1 (es) 2018-02-09
WO2017004006A1 (en) 2017-01-05
CA2990012A1 (en) 2017-01-05
CN107771184B (zh) 2022-11-01
MX395257B (es) 2025-03-25
EP3313880B1 (en) 2025-08-06
US20240336695A1 (en) 2024-10-10
IL256499A (en) 2018-02-28
MX2017016253A (es) 2018-04-20
MX2022002504A (es) 2022-04-06
CN115838427A (zh) 2023-03-24
BR112017027549A2 (pt) 2018-09-11
AU2016285913B2 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
CL2017003427A1 (es) Anticuerpos para cd40
CY1124033T1 (el) Δοσολογια και χορηγηση μη φουκοζυλιωμενων αντισωματων anti-cd40
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
MX2021008053A (es) Metodos para monitorear y terapias para usarse en tratar el cancer.
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201691974A1 (ru) Антитела против ox40 и способы их применения
MX395147B (es) Formulación de anticuerpo anti-cgrp.
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201691991A1 (ru) Мультиспецифические антитела
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201691541A1 (ru) Новые анти-baff антитела
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
CL2017003147A1 (es) Moduladores de receptor nuclear
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
BR112017012381A2 (pt) imunoterapia para doença angiogênica
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
MX2017001686A (es) Anticuerpos anti-ceramida.
EA201790990A1 (ru) Мультипептидный т-специфичный иммунотерапевтический препарат для лечения метастазов рака в головном мозге